Rani Therapeutics Holdings, Inc
1.6600-0.23 (-12.2%)
Oct 29, 4:00:00 PM EDT · NasdaqGM · RANI · USD
Key Stats
Market Cap
121.17MP/E (TTM)
-Basic EPS (TTM)
-0.90Dividend Yield
0%Recent Filings
8-K
Rani raises $60M, partners with Chugai
Rani Therapeutics secured $60.3 million in gross proceeds from a private placement of 42.6 million shares and warrants, plus 82.4 million pre-funded warrants, at $0.48 per share, while converting $6 million of existing debt into equity. Simultaneously, it inked a collaboration with Chugai Pharmaceutical, pocketing $10 million upfront for combining Chugai's hemophilia antibody with Rani's oral delivery tech, plus up to $175 million in milestones and royalties. This dual move bolsters Rani's cash runway for pipeline advancement, yet hinges on stockholder approval for warrant exercises.
8-K
Rani's Chugai collab and RT-114 data
Rani Therapeutics announced a strategic research collaboration with Chugai in May 2025 for two undisclosed molecules, validating RaniPill's oral delivery with bioavailability matching subcutaneous routes. Preclinical data for obesity candidate RT-114 showed bioequivalence in canines, paving the way for Phase 1 initiation in late 2025. Cash burn eased to $11.2 million net loss, bolstered by $7.3 million from warrant exercises and a direct offering, yet reserves dipped to $10.2 million. Funding remains tight amid pipeline advances.
10-Q
Q2 FY2025 results
Rani Therapeutics narrowed its Q2 operating loss to $10.5 million from $12.5 million a year earlier, thanks to lower research and development and general administrative costs, while YTD net loss improved 15% to $24.0 million on $0.2 million in contract revenue from Chugai evaluation services. Operating cash burn eased to $13.9 million for the half, with free cash flow not disclosed in the 10-Q. Cash stood at $10.2 million against $17.2 million in debt maturing August 2026 at 14.58%, and a July offering added $3.0 million. Preclinical wins for RT-114 and RT-116 bolster the oral delivery pipeline. Yet Nasdaq delisting risks loom if the $1 bid price holds.
8-K
Rani raises $3M via shares, warrants
Rani Therapeutics inked a securities purchase agreement on July 14, 2025, to sell 4.35 million Class A shares and pre-funded warrants for 3.15 million more at $0.40 per share, netting about $3.0 million before fees. Closing hits July 16, funding working capital while locking insiders for 45 days and halting new issuances for 10 days post-close. Cash bolsters runway, yet dilutes shareholders amid biotech pressures.
8-K
Nasdaq delisting warning issued
Rani Therapeutics received a Nasdaq notice on June 20, 2025, for failing to maintain a $1 minimum bid price over 30 business days, violating Listing Rule 5450(a)(1). The company has 180 days until December 17, 2025, to fix it by hitting $1 for 10 straight days. Non-compliance risks delisting, though a transfer to Nasdaq Capital Market could buy another 180 days if other standards hold. Rani plans to track its stock and weigh options like a reverse split. No guarantees on success.
IPO
Employees
Sector
Industry
ENTX
Entera Bio Ltd.
2.73+0.21
ORKA
Oruka Therapeutics, Inc.
27.61+0.17
PPCB
Propanc Biopharma, Inc.
1.31-0.11
RADX
Radiopharm Theranostics Limited
5.01-0.05
RAPP
Rapport Therapeutics, Inc.
27.01-0.38
RLMD
Relmada Therapeutics, Inc.
2.45+0.00
RVPH
Reviva Pharmaceuticals Holdings
0.59+0.01
TARA
Protara Therapeutics, Inc.
5.20+0.11
VANI
Vivani Medical, Inc.
1.77+0.10
VKTX
Viking Therapeutics, Inc.
35.22+0.29